Summary of Illumina Q4 2025 Earnings Call

1Key Financial Results and Metrics

Revenue: Q4 revenue reached $1.16 billion, up 5% year-over-year (4% on a constant currency basis). Excluding Greater China, revenue grew 7%.

Clinical Consumables: Revenue grew 20% year-over-year (ex-China), driven by increased adoption of sequencing-based diagnostic tests.

Gross Margin: Non-GAAP gross margin was 67%, down 40 basis points year-over-year, primarily due to tariffs.

Operating Margin: Non-GAAP operating margin improved to 23.7%, up 400 basis points year-over-year.

Earnings Per Share (EPS): Non-GAAP EPS was $1.35, a 42% increase year-over-year, exceeding guidance.

Free Cash Flow: Generated $321 million in Q4, totaling $1.1 billion for the year.

2Strategic Updates and Business Highlights

Growth Strategy: Illumina's strategy focuses on three pillars: core sequencing, scaling multiomics, and expanding services/data/software capabilities.

Acquisition of Somalogic: Completed acquisition for $350 million to enhance multiomics capabilities, expected to strengthen Illumina's position in the proteomics market.

BioInsight Launch: Introduced BioInsight, which integrates sequencing, CRISPR tools, and AI to enhance drug discovery processes.

NovaSeq X Performance: Strong demand for NovaSeq X instruments, with Q4 placements being the second highest since launch, indicating robust growth in clinical applications.

3Forward Guidance and Outlook

2026 Revenue Guidance: Expected total revenue of $4.5 billion to $4.6 billion, representing 4% to 6% growth, with organic growth of 2% to 4% (excluding China).

Clinical Growth: Anticipated double-digit to mid-teens growth in clinical consumables, while research consumables are expected to decline mid to high single digits.

Operating Margin: Projected operating margins of 23.3% to 23.5% for 2026, with EPS guidance of $5.00 to $5.20, including dilution from the Somalogic acquisition.

4Bad News, Challenges, or Points of Concern

Research Market Challenges: Continued uncertainty in the research funding environment, with expectations of mid to high single-digit declines in research consumables.

China Market Risks: Sales in Greater China were down 55% due to export restrictions, with ongoing discussions about the ability to import instruments into the country.

Competitive Pressures: Competitors are pushing for lower pricing per genome, which may impact Illumina's pricing strategy and market share.

5Notable Q&A Insights

Operating Margin Expectations: Analysts inquired about the assumptions behind operating margin guidance, with management indicating a commitment to long-term targets despite dilution from acquisitions.

Clinical vs. Research Growth: Clarifications were provided on the expected growth rates for clinical versus research segments, with clinical expected to drive overall growth.

BioInsight's Potential: Discussion on how BioInsight could monetize AI capabilities in drug discovery, with significant interest from pharma partners noted.

Academic Market Dynamics: Management acknowledged the challenges in the academic market but expressed optimism about improving conditions with potential NIH funding increases. Overall, Illumina's Q4 2025 results reflect a strong finish to the year with significant growth in clinical consumables and a positive outlook for 2026, despite challenges in the research market and geopolitical risks in China.